Results:
While acamprosate was not associated with a significantly greater rate of reduction in binge eating episode frequency or any other measure in the primary longitudinal analysis, in the endpoint analysis it was associated with statistically significant improvements in binge day frequency and measures of obsessive - compulsiveness of binge eating, food craving, and quality of life.
Not exact matches
Review: in alcohol use disorders,
acamprosate is more effective for inducing abstinence
while naltrexone is more effective for reducing heavy drinking and craving